

Frédéric Frazard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8992411/publications.pdf>

Version: 2024-02-01

134
papers

4,103
citations

76326

40
h-index

144013

57
g-index

136
all docs

136
docs citations

136
times ranked

4616
citing authors

#	ARTICLE	IF	CITATIONS
1	Comparative evaluation of meglumine antimoniate encapsulated in a mixture of conventional and PEGylated liposomes and immunotherapy using an anti-canine IL-10 receptor-blocking monoclonal antibody on canine visceral leishmaniasis. <i>Molecular Immunology</i> , 2022, 141, 70-78.	2.2	3
2	The Potential of 2-Substituted Quinolines as Antileishmanial Drug Candidates. <i>Molecules</i> , 2022, 27, 2313.	3.8	9
3	Formulation of Amphotericin B in PEGylated Liposomes for Improved Treatment of Cutaneous Leishmaniasis by Parenteral and Oral Routes. <i>Pharmaceutics</i> , 2022, 14, 989.	4.5	14
4	Use of liposomal nanoformulations in antileishmania therapy: challenges and perspectives. <i>Journal of Liposome Research</i> , 2021, 31, 169-176.	3.3	6
5	Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis. <i>Biomedicine and Pharmacotherapy</i> , 2021, 134, 111120.	5.6	6
6	A TLR9-adjuvanted vaccine formulated into dissolvable microneedle patches or cationic liposomes protects against leishmaniasis after skin or subcutaneous immunization. <i>International Journal of Pharmaceutics</i> , 2020, 586, 119390.	5.2	29
7	Reactive oxygen species generating photosynthesized ferromagnetic iron oxide nanorods as promising antileishmanial agent. <i>Nanomedicine</i> , 2020, 15, 755-771.	3.3	7
8	Preclinical Gold Complexes as Oral Drug Candidates to Treat Leishmaniasis Are Potent Trypanothione Reductase Inhibitors. <i>ACS Infectious Diseases</i> , 2020, 6, 1121-1139.	3.8	36
9	Therapeutic Efficacy of a Mixed Formulation of Conventional and PEGylated Liposomes Containing Meglumine Antimoniate, Combined with Allopurinol, in Dogs Naturally Infected with <i>Leishmania infantum</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 2020, 64, .	3.2	7
10	Combination oral therapy against <i>Leishmania amazonensis</i> infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine. <i>Parasitology Research</i> , 2019, 118, 3077-3084.	1.6	13
11	Recent advances in amphotericin B delivery strategies for the treatment of leishmaniases. <i>Expert Opinion on Drug Delivery</i> , 2019, 16, 1063-1079.	5.0	43
12	Liposomes for drug delivery in stroke. <i>Brain Research Bulletin</i> , 2019, 152, 246-256.	3.0	44
13	American tegumentary leishmaniasis in Brazil: a critical review of the current therapeutic approach with systemic meglumine antimoniate and short-term possibilities for an alternative treatment. <i>Tropical Medicine and International Health</i> , 2019, 24, 380-391.	2.3	32
14	Analytical methodology for the simultaneous determination of NMG-Sb(v), iSb(v), and iSb(iii) species by anion exchange liquid chromatography in Glucantime® and its biological application in Wistar rat urine. <i>Journal of Analytical Atomic Spectrometry</i> , 2019, 34, 203-213.	3.0	5
15	In vitro antileishmanial activity of leaf and stem extracts of seven Brazilian plant species. <i>Journal of Ethnopharmacology</i> , 2019, 232, 155-164.	4.1	11
16	Seasonality study of essential oil from leaves of <i>Cymbopogon densiflorus</i> and nanoemulsion development with antioxidant activity. <i>Flavour and Fragrance Journal</i> , 2019, 34, 5-14.	2.6	42
17	Antimony resistance in <i>Leishmania (Viannia) braziliensis</i> clinical isolates from atypical lesions associates with increased ARM56/ARM58 transcripts and reduced drug uptake. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2019, 114, e190111.	1.6	15
18	A long-lasting oral preformulation of the angiotensin II AT1 receptor antagonist losartan. <i>Drug Development and Industrial Pharmacy</i> , 2018, 44, 1498-1505.	2.0	9

#	ARTICLE	IF	CITATIONS
19	GABA-containing liposomes: neuroscience applications and translational perspectives for targeting neurological diseases. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2018, 14, 781-788.	3.3	18
20	Hepatic fibropoiesis in dogs naturally infected with <i>Leishmania (Leishmania) infantum</i> treated with liposome-encapsulated meglumine antimoniate and allopurinol. <i>Veterinary Parasitology</i> , 2018, 250, 22-29.	1.8	8
21	Canine Leishmaniasis: An Overview of the Current Status and Strategies for Control. <i>BioMed Research International</i> , 2018, 2018, 1-12.	1.9	95
22	Accelerated Blood Clearance (ABC) Phenomenon Favors the Accumulation of Tartar Emetic in Pegylated Liposomes in BALB/c Mice Liver. <i>Pathology Research International</i> , 2018, 2018, 1-7.	1.4	8
23	Recent Advances in the Therapeutic and Diagnostic Use of Liposomes and Carbon Nanomaterials in Ischemic Stroke. <i>Frontiers in Neuroscience</i> , 2018, 12, 453.	2.8	39
24	Growth arrested live-attenuated <i>Leishmania infantum</i> KHARON1 null mutants display cytokinesis defect and protective immunity in mice. <i>Scientific Reports</i> , 2018, 8, 11627.	3.3	16
25	Efficacy of Meglumine Antimoniate in a Low Polymerization State Orally Administered in a Murine Model of Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	3.2	7
26	Mixed Formulation of Conventional and Pegylated Meglumine Antimoniate-Containing Liposomes Reduces Inflammatory Process and Parasite Burden in <i>Leishmania infantum</i> -Infected BALB/c Mice. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	17
27	Biophysical and Pharmacological Characterization of Energy-Dependent Efflux of Sb in Laboratory-Selected Resistant Strains of <i>Leishmania (Viannia)</i> Subgenus. <i>Frontiers in Cell and Developmental Biology</i> , 2017, 5, 24.	3.7	4
28	Extracellular Vesicles from Adipose-Derived Mesenchymal Stem/Stromal Cells Accelerate Migration and Activate AKT Pathway in Human Keratinocytes and Fibroblasts Independently of miR-205 Activity. <i>Stem Cells International</i> , 2017, 2017, 1-14.	2.5	62
29	Nanostructures for Improved Antimonial Therapy of Leishmaniasis. , 2017, , 419-437.		2
30	Organometallic Compounds in Chemotherapy Against <i>Leishmania</i> . <i>RSC Drug Discovery Series</i> , 2017, , 199-223.	0.3	1
31	Polarity-sensitive nanocarrier for oral delivery of Sb(V) and treatment of cutaneous leishmaniasis. <i>International Journal of Nanomedicine</i> , 2016, 11, 2305.	6.7	17
32	Silver and Nitrate Oppositely Modulate Antimony Susceptibility through Aquaglyceroporin 1 in <i>Leishmania (Viannia)</i> Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 4482-4489.	3.2	9
33	Liposome-entrapped GABA modulates the expression of nNOS in NG108-15 cells. <i>Journal of Neuroscience Methods</i> , 2016, 273, 55-63.	2.5	13
34	Redox-Active Metal Complexes in Trypanosomatids. <i>Oxidative Stress in Applied Basic Research and Clinical Practice</i> , 2016, , 669-681.	0.4	0
35	Cytotoxicity and apoptotic activity of novel organobismuth(V) and organoantimony(V) complexes in different cancer cell lines. <i>European Journal of Medicinal Chemistry</i> , 2016, 109, 254-267.	5.5	62
36	Î±-Tocopherol succinate improves encapsulation and anticancer activity of doxorubicin loaded in solid lipid nanoparticles. <i>Colloids and Surfaces B: Biointerfaces</i> , 2016, 140, 246-253.	5.0	49

#	ARTICLE	IF	CITATIONS
37	Injectable Liposomal Formulations: Systematic Analysis for Regulatory Purposes. <i>Pharmaceutical Nanotechnology</i> , 2016, 4, 88-108.	1.5	0
38	Gadolinium(III) Complexes with N-Alkyl-N-methylglucamine Surfactants Incorporated into Liposomes as Potential MRI Contrast Agents. <i>Bioinorganic Chemistry and Applications</i> , 2015, 2015, 1-8.	4.1	8
39	Nanoparticle phosphate-based composites as vehicles for antimony delivery to macrophages: possible use in leishmaniasis. <i>Journal of Materials Chemistry B</i> , 2015, 3, 9250-9259.	5.8	10
40	Nanoemulsions loaded with amphotericin B: A new approach for the treatment of leishmaniasis. <i>European Journal of Pharmaceutical Sciences</i> , 2015, 70, 125-131.	4.0	58
41	Intrachromosomal Amplification, Locus Deletion and Point Mutation in the Aquaglyceroporin AQP1 Gene in Antimony Resistant <i>Leishmania (Viannia) guyanensis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2015, 9, e0003476.	3.0	62
42	Nanocarriers for Improved Delivery of Angiotensin-(1-7)., 2015, , 275-279.		0
43	Synthesis and characterization of bismuth(III) and antimony(V) porphyrins: high antileishmanial activity against antimony-resistant parasite. <i>Journal of Biological Inorganic Chemistry</i> , 2015, 20, 771-779.	2.6	24
44	Cardiovascular and behavioral effects produced by administration of liposome-entrapped GABA into the rat central nervous system. <i>Neuroscience</i> , 2015, 285, 60-69.	2.3	15
45	Association of water extract of green propolis and liposomal meglumine antimoniate in the treatment of experimental visceral leishmaniasis. <i>Parasitology Research</i> , 2014, 113, 533-543.	1.6	24
46	Complexes of different nitrogen donor heterocyclic ligands with SbCl ₃ and PhSbCl ₂ as potential antileishmanial agents against Sb(III)-sensitive and -resistant parasites. <i>Journal of Inorganic Biochemistry</i> , 2014, 132, 30-36.	3.5	17
47	Hepatotoxicity of Pentavalent Antimonial Drug: Possible Role of Residual Sb(III) and Protective Effect of Ascorbic Acid. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 481-488.	3.2	50
48	Antimony transport mechanisms in resistant leishmania parasites. <i>Biophysical Reviews</i> , 2014, 6, 119-132.	3.2	43
49	Development and characterization of multilamellar liposomes containing pyridostigmine. <i>Pharmaceutical Development and Technology</i> , 2014, 19, 454-459.	2.4	2
50	Mixed formulation of conventional and pegylated liposomes as a novel drug delivery strategy for improved treatment of visceral leishmaniasis. <i>Expert Opinion on Drug Delivery</i> , 2014, 11, 1551-1560.	5.0	23
51	Mixed Antimony(V) Complexes with Different Sugars to Modulate the Oral Bioavailability of Pentavalent Antimonial Drugs. <i>Molecules</i> , 2014, 19, 5478-5489.	3.8	12
52	Novel Triphenylantimony(V) and Triphenylbismuth(V) Complexes with Benzoic Acid Derivatives: Structural Characterization, in Vitro Antileishmanial and Antibacterial Activities and Cytotoxicity against Macrophages. <i>Molecules</i> , 2014, 19, 6009-6030.	3.8	66
53	Association of Liposome-Encapsulated Trivalent Antimonial with Ascorbic Acid: An Effective and Safe Strategy in the Treatment of Experimental Visceral Leishmaniasis. <i>PLoS ONE</i> , 2014, 9, e104055.	2.5	14
54	Unexpectedly high levels of antimony (III) in the pentavalent antimonial drug Glucantime: insights from a new voltammetric approach. <i>Analytical and Bioanalytical Chemistry</i> , 2013, 405, 5201-5214.	3.7	18

#	ARTICLE	IF	CITATIONS
55	Activation of Leishmania spp. leishporin: evidence that dissociation of an inhibitor not only improves its lipid-binding efficiency but also endows it with the ability to form pores. <i>Parasitology Research</i> , 2013, 112, 3305-3314.	1.6	5
56	Molecular characterization of the MRPA transporter and antimony uptake in four New World Leishmania spp. susceptible and resistant to antimony. <i>International Journal for Parasitology: Drugs and Drug Resistance</i> , 2013, 3, 143-153.	3.4	40
57	Amphiphilic Antimony(V) Complexes for Oral Treatment of Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 4229-4236.	3.2	30
58	Potent naphthoquinones against antimony-sensitive and -resistant Leishmania parasites: Synthesis of novel β - and α -lapachone-based 1,2,3-triazoles by copper-catalyzed azide-alkyne cycloaddition. <i>European Journal of Medicinal Chemistry</i> , 2013, 63, 523-530.	5.5	89
59	Chemistry of antimony-based drugs in biological systems and studies of their mechanism of action. <i>Reviews in Inorganic Chemistry</i> , 2013, 33, 1-12.	4.1	19
60	Improved pharmacological profile of the lipophilic antitumor dichloro-(N-dodecyl)-propanediamine-platinum(II) complex after incorporation into pegylated liposomes. <i>Anti-Cancer Drugs</i> , 2013, 24, 131-139.	1.4	7
61	Complement activation-related pseudoallergy in dogs following intravenous administration of a liposomal formulation of meglumine antimoniate. <i>Pesquisa Veterinaria Brasileira</i> , 2013, 33, 1016-1020.	0.5	2
62	Cytotoxicity and <i>In Vitro</i> Antileishmanial Activity of Antimony (V), Bismuth (V), and Tin (IV) Complexes of Lapachol. <i>Bioinorganic Chemistry and Applications</i> , 2013, 2013, 1-7.	4.1	35
63	Relationship between clinical and pathological signs and severity of canine leishmaniasis. <i>Brazilian Journal of Veterinary Parasitology</i> , 2013, 22, 373-378.	0.7	20
64	Intracerebroventricular injection of liposome-entrapped GABA attenuates the renal sympathetic nerve activity response evoked by central administration of bicuculline in spontaneously hypertensive rats. <i>FASEB Journal</i> , 2013, 27, 1b852.	0.5	0
65	Efficacy of Combined Therapy with Liposome-Encapsulated Meglumine Antimoniate and Allopurinol in Treatment of Canine Visceral Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2858-2867.	3.2	47
66	Improved Antileishmanial Activity of Dppz through Complexation with Antimony(III) and Bismuth(III): Investigation of the Role of the Metal. <i>Molecules</i> , 2012, 17, 12622-12635.	3.8	34
67	Insights into the multi-equilibrium, superstructure system based on β -cyclodextrin and a highly water soluble guest. <i>International Journal of Pharmaceutics</i> , 2012, 439, 207-215.	5.2	15
68	Heparan Sulfate Proteoglycan-Mediated Entry Pathway for Charged Tri-Platinum Compounds: Differential Cellular Accumulation Mechanisms for Platinum. <i>Molecular Pharmaceutics</i> , 2012, 9, 1795-1802.	4.6	34
69	Greater binding affinity of trivalent antimony to a CCCH zinc finger domain compared to a CCHC domain of kinetoplastid proteins. <i>Metallomics</i> , 2012, 4, 433.	2.4	26
70	Intracerebroventricular injection of liposome-entrapped GABA attenuates the renal sympathetic nerve activity response evoked by central administration of bicuculline in anesthetized rats. <i>FASEB Journal</i> , 2012, 26, 1091.38.	0.5	1
71	Determination of sphingomyelinase-D activity of <i>Loxosceles</i> venoms in sphingomyelin/cholesterol liposomes containing horseradish peroxidase. <i>Toxicon</i> , 2011, 57, 574-579.	1.6	9
72	Antimony(V) and Bismuth(V) Complexes of Lapachol: Synthesis, Crystal Structure and Cytotoxic Activity. <i>Molecules</i> , 2011, 16, 10314-10323.	3.8	51

#	ARTICLE	IF	CITATIONS
73	Protection against the toxic effects of <i>Loxosceles intermedia</i> spider venom elicited by mimotope peptides. <i>Vaccine</i> , 2011, 29, 7992-8001.	3.8	36
74	Occurrence of anti- <i>Neospora caninum</i> and anti- <i>Toxoplasma gondii</i> antibodies in dogs with visceral leishmaniasis. <i>Pesquisa Veterinaria Brasileira</i> , 2011, 31, 527-532.	0.5	4
75	Interaction of arsenite with a zinc finger CCHC peptide: Evidence for formation of an As ³⁺ -Zn-peptide mixed complex. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 1753-1758.	3.5	10
76	Gene Expression Profiling and Molecular Characterization of Antimony Resistance in <i>Leishmania amazonensis</i> . <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1167.	3.0	69
77	Liposome-Encapsulated Neuropeptides for Site-Specific Microinjection. <i>Methods in Molecular Biology</i> , 2011, 789, 343-355.	0.9	7
78	Prolonged absorption of antimony(V) by the oral route from non- β -cyclodextrin inclusion meglumine antimoniate β -cyclodextrin conjugates. <i>Biopharmaceutics and Drug Disposition</i> , 2010, 31, 109-119.	1.9	15
79	LyeTx I, a potent antimicrobial peptide from the venom of the spider <i>Lycosa erythrognatha</i> . <i>Amino Acids</i> , 2010, 39, 135-144.	2.7	55
80	New insights into the mode of action of ultradeformable vesicles using calcein as hydrophilic fluorescent marker. <i>European Journal of Pharmaceutical Sciences</i> , 2010, 39, 90-96.	4.0	41
81	Novel platinum(II) complexes of long chain aliphatic diamine ligands with oxalato as the leaving group: comparative cytotoxic activity relative to chloride precursors. <i>Journal of the Brazilian Chemical Society</i> , 2010, 21, 1961-1967.	0.6	9
82	Liposome encapsulation of lipophilic N-alkyl-propanediamine platinum complexes: impact on their cytotoxic activity and influence of the carbon chain length. <i>Journal of the Brazilian Chemical Society</i> , 2010, 21, 1861-1866.	0.6	1
83	Influence of the nucleobase on the physicochemical characteristics and biological activities of SbV-ribonucleoside complexes. <i>Journal of the Brazilian Chemical Society</i> , 2010, 21, 1258-1265.	0.6	7
84	Prolonged cardioprotective effect of pyridostigmine encapsulated in liposomes. <i>Life Sciences</i> , 2010, 86, 17-23.	4.3	7
85	Reduced cardiovascular alterations of tartar emetic administered in long-circulating liposomes in rats. <i>Toxicology Letters</i> , 2010, 199, 234-238.	0.8	10
86	New delivery strategies for the old pentavalent antimonial drugs. <i>Expert Opinion on Drug Delivery</i> , 2010, 7, 1343-1358.	5.0	69
87	Membrane binding requirements for the cytolytic activity of <i>Leishmania amazonensis</i> leishporin. <i>FEBS Letters</i> , 2009, 583, 3209-3214.	2.8	9
88	Chapter 3 Physicochemical and Pharmacokinetic Characterization of Ultradeformable Vesicles using Calcein as Hydrophilic Fluorescent Marker. <i>Behavior Research Methods</i> , 2009, , 65-85.	4.0	1
89	Pentavalent Antimonials: New Perspectives for Old Drugs. <i>Molecules</i> , 2009, 14, 2317-2336.	3.8	328
90	New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate. <i>Journal of Inorganic Biochemistry</i> , 2008, 102, 656-665.	3.5	54

#	ARTICLE	IF	CITATIONS
91	Enhanced oral delivery of antimony from meglumine antimoniate/ β -cyclodextrin nanoassemblies. <i>International Journal of Pharmaceutics</i> , 2008, 347, 102-108.	5.2	39
92	Interaction of trivalent antimony with a CCHC zinc finger domain: potential relevance to the mechanism of action of antimonial drugs. <i>Chemical Communications</i> , 2008, , 4828.	4.1	42
93	Effect of cholesterol on the interaction of the amphibian antimicrobial peptide DD K with liposomes. <i>Peptides</i> , 2008, 29, 15-24.	2.4	45
94	Reduced Tissue Parasitic Load and Infectivity to Sand Flies in Dogs Naturally Infected by <i>Leishmania</i> (<i>L. infantum</i>) Treated with Antimicrobial Agents and Chemotherapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2008, 52, 2564-2572.	3.2	67
95	A novel approach based on nanotechnology for investigating the chronic actions of short-lived peptides in specific sites of the brain. <i>Regulatory Peptides</i> , 2007, 138, 59-65.	1.9	4
96	Kinetics of antimony(V) reduction by L-cysteine: pharmacological implications and application to the determination of antimony in pentavalent antimonial drugs. <i>Journal of the Brazilian Chemical Society</i> , 2006, 17, 1642-1650.	0.6	7
97	Chapter 2 Liposomes as a Tool for the Study of the Chronic Actions of Short-lived Peptides in Specific Sites of the Brain. <i>Behavior Research Methods</i> , 2006, 5, 25-40.	4.0	0
98	Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. <i>International Journal of Pharmaceutics</i> , 2006, 315, 140-147.	5.2	45
99	Mode of action of β -cyclodextrin as an absorption enhancer of the water-soluble drug meglumine antimoniate. <i>International Journal of Pharmaceutics</i> , 2006, 325, 39-47.	5.2	37
100	Synthesis and characterization of Sb(V)-adenosine and Sb(V)-guanosine complexes in aqueous solution. <i>Inorganica Chimica Acta</i> , 2006, 359, 159-167.	2.4	18
101	Characterization of reactions of antimoniate and meglumine antimoniate with a guanine ribonucleoside at different pH. <i>BioMetals</i> , 2006, 19, 573-581.	4.1	22
102	Role of residual Sb(III) in meglumine antimoniate cytotoxicity and MRP1-mediated resistance. <i>Chemico-Biological Interactions</i> , 2006, 160, 217-224.	4.0	26
103	Lipossomas: propriedades físico-químicas e farmacológicas, aplicações na quimioterapia à base de antimônio. <i>Química Nova</i> , 2005, 28, 511-518.	0.3	58
104	Characterization of Liposomes Containing 5-Fluorouracil in Hydrophilic Gel Using Atomic Force Microscopy. <i>Microscopy and Microanalysis</i> , 2005, 11, 62-65.	0.4	2
105	Site-specific microinjection of liposomes into the brain for local infusion of a short-lived peptide. <i>Journal of Controlled Release</i> , 2004, 95, 301-307.	9.9	21
106	Oral Delivery of Meglumine Antimoniate- β -Cyclodextrin Complex for Treatment of Leishmaniasis. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 100-103.	3.2	80
107	Thiol-induced reduction of antimony(V) into antimony(III): a comparative study with trypanothione, cysteinyl-glycine, cysteine and glutathione. <i>BioMetals</i> , 2003, 16, 441-446.	4.1	122
108	Pentavalent organoantimonial derivatives: two simple and efficient synthetic methods for meglumine antimonate. <i>Applied Organometallic Chemistry</i> , 2003, 17, 226-231.	3.5	31

#	ARTICLE	IF	CITATIONS
109	Enhanced schistosomicidal efficacy of tartar emetic encapsulated in pegylated liposomes. <i>International Journal of Pharmaceutics</i> , 2003, 255, 227-230.	5.2	23
110	Antimony(V) complex formation with adenine nucleosides in aqueous solution. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2002, 1570, 192-198.	2.4	51
111	Diffusion limited field induced aggregation of magnetic liposomes. <i>Brazilian Journal of Physics</i> , 2001, 31, 356.	1.4	7
112	Vertical toxoplasmosis in a murine model. Protection after immunization with antigens of <i>Toxoplasma gondii</i> incorporated into liposomes. <i>Memorias Do Instituto Oswaldo Cruz</i> , 2001, 96, 99-104.	1.6	28
113	P-Glycoprotein preferentially effluxes anthracyclines containing free basic versus charged amine. <i>FEBS Journal</i> , 2001, 268, 1561-1567.	0.2	34
114	Long-Lasting Cardiovascular Effects of Liposome-Entrapped Angiotensin-(1-7) at the Rostral Ventrolateral Medulla. <i>Hypertension</i> , 2001, 38, 1266-1271.	2.7	42
115	Glutathione-Induced Conversion of Pentavalent Antimony to Trivalent Antimony in Meglumine Antimoniate. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 913-916.	3.2	121
116	Protection against Toxoplasmosis in Mice Immunized with Different Antigens of <i>Toxoplasma gondii</i> Incorporated into Liposomes. <i>Memorias Do Instituto Oswaldo Cruz</i> , 1999, 94, 485-490.	1.6	17
117	Physico-chemical characterization of meglumine antimoniate. <i>BioMetals</i> , 1999, 12, 63-66.	4.1	23
118	Energy-dependent efflux from <i>Leishmania promastigotes</i> of substrates of the mammalian multidrug resistance pumps. <i>Molecular and Biochemical Parasitology</i> , 1999, 100, 73-84.	1.1	42
119	Permeability of lipid bilayer to anthracycline derivatives. Role of the bilayer composition and of the temperature. <i>Lipids and Lipid Metabolism</i> , 1998, 1389, 13-22.	2.6	44
120	Encapsulation of native crotoxin in liposomes: A safe approach for the production of antivenom and vaccination against <i>Crotalus durissus terrificus</i> venom. <i>Toxicon</i> , 1997, 35, 91-100.	1.6	28
121	Evaluation of the schistosomicidal efficacy of liposome - Entrapped Oxamniquine. <i>Revista Do Instituto De Medicina Tropical De Sao Paulo</i> , 1997, 39, 97-100.	1.1	15
122	Fluorinated Phospholipid-Based Vesicles as Potential Drug Carriers: Encapsulation/Sustaining of Drugs and Stability in Human Serum. <i>Artificial Cells, Blood Substitutes, and Biotechnology</i> , 1994, 22, 1403-1408.	0.9	2
123	Novel liposome systems based on the incorporation of (perfluoroalkyl) alkenes (FmHnE) into the bilayer of phospholipid liposomes. <i>Colloids and Surfaces A: Physicochemical and Engineering Aspects</i> , 1994, 88, 223-233.	4.7	27
124	Fluorometric determination in biological fluids of the release kinetics of liposome-entrapped doxorubicin. <i>Journal of Liposome Research</i> , 1994, 4, 1063-1073.	3.3	5
125	Incorporation of a perfluoroalkylalkane (RFRH) into the phospholipid bilayer of dmpc liposomes results in greater encapsulation stability. <i>Journal of Liposome Research</i> , 1994, 4, 1017-1028.	3.3	20
126	Permeability and stability in buffer and in human serum of fluorinated phospholipid-based liposomes. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1994, 1192, 61-70.	2.6	60

#	ARTICLE	IF	CITATIONS
127	Fluorinated phosphatidylcholine-based liposomes: H ⁺ /Na ⁺ permeability, active doxorubicin encapsulation and stability in human serum. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1994, 1194, 61-68.	2.6	50
128	Extended in vivo blood circulation time of fluorinated liposomes. <i>FEBS Letters</i> , 1993, 336, 481-484.	2.8	65
129	DNA-containing liposomes as a model for the study of cell membrane permeation by anthracycline derivatives. <i>Biochemistry</i> , 1991, 30, 5038-5043.	2.5	48
130	Determination of the osmotic active drug concentration in the cytoplasm of anthracycline-resistant and -sensitive K562 cells. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1991, 1091, 29-35.	4.1	50
131	Comparison of the membrane transport of anthracycline derivatives in drug-resistant and drug-sensitive K562 cells. <i>FEBS Journal</i> , 1991, 196, 483-491.	0.2	89
132	Comparison of the binding of anthracycline derivatives to purified DNA and to cell nuclei. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1990, 1036, 121-127.	2.4	58
133	Anthracycline incorporation in human lymphocytes. Kinetics of uptake and nuclear concentration. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 1989, 1013, 109-117.	4.1	81
134	Membrane-phorbol ester interactions monitored by circular dichroism. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1989, 979, 316-320.	2.6	6